Literature DB >> 12524235

Influence of factor VIIa and phospholipids on coagulation in "acquired" hemophilia.

Saulius Butenas1, Kathleen E Brummel, Sara G Paradis, Kenneth G Mann.   

Abstract

OBJECTIVE: This study was performed to evaluate the influences of phospholipids and recombinant factor VIIa (rFVIIa) on thrombin generation and clot formation in "acquired" hemophilia B. METHODS AND
RESULTS: A synthetic mixture corresponding to hemophilia A (SHA) and "acquired" hemophilia B blood (AHBB) manufactured in vitro by an anti-FIX antibody were used in this study. With 10 pmol/L tissue factor (TF), 10 nmol/L rFVIIa, and saturating phospholipid, established thrombin generation in SHA was similar to that observed in the presence of factor VIII and rFVIIa at physiological concentrations. At lower phospholipid concentrations, thrombin generation was delayed and reduced. With 5 pmol/L TF, contact pathway-inhibited AHBB clotted later than normal blood and showed reduced clot stability and thrombin generation. These parameters of effectiveness were increased by the addition of phospholipids to AHBB, which restored clot stability and increased thrombin generation. No correction of clot formation or thrombin generation was observed when rFVIIa and phospholipids were added to AHBB in the absence of TF.
CONCLUSIONS: The influence of rFVIIa is dependent on TF, and phospholipids substantially increase the hemostatic (or thrombotic) potential of rFVIIa/TF.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12524235     DOI: 10.1161/01.atv.0000042081.57854.a2

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  14 in total

1.  Membrane binding events in the initiation and propagation phases of tissue factor-initiated zymogen activation under flow.

Authors:  Laura M Haynes; Yves C Dubief; Kenneth G Mann
Journal:  J Biol Chem       Date:  2011-12-20       Impact factor: 5.157

Review 2.  Recombinant factor VIIa (Eptacog Alfa): a review of its use in congenital or acquired haemophilia and other congenital bleeding disorders.

Authors:  M Asif A Siddiqui; Lesley J Scott
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 3.  Recombinant factor VIIa: a review on its clinical use.

Authors:  Massimo Franchini
Journal:  Int J Hematol       Date:  2006-02       Impact factor: 2.490

4.  To the editor: Is von Willebrand factor a hormone that regulates a coagulation mechanism?

Authors:  Lewis S Coleman
Journal:  World J Surg       Date:  2006-03       Impact factor: 3.352

5.  The endothelial protein C receptor enhances hemostasis of FVIIa administration in hemophilic mice in vivo.

Authors:  Giulia Pavani; Lacramioara Ivanciu; Armida Faella; Oscar A Marcos-Contreras; Paris Margaritis
Journal:  Blood       Date:  2014-06-23       Impact factor: 22.113

6.  Thrombin generation and bleeding in haemophilia A.

Authors:  K E Brummel-Ziedins; M F Whelihan; M Gissel; K G Mann; G E Rivard
Journal:  Haemophilia       Date:  2009-06-26       Impact factor: 4.287

7.  Recombinant factor VIIa analog NN1731 (V158D/E296V/M298Q-FVIIa) enhances fibrin formation, structure and stability in lipidated hemophilic plasma.

Authors:  Laura D Gray; Michael A Hussey; Brittany M Larson; Kellie R Machlus; Robert A Campbell; Gary Koch; Mirella Ezban; Ulla Hedner; Alisa S Wolberg
Journal:  Thromb Res       Date:  2011-05-10       Impact factor: 3.944

8.  The tissue factor requirement in blood coagulation.

Authors:  Thomas Orfeo; Saulius Butenas; Kathleen E Brummel-Ziedins; Kenneth G Mann
Journal:  J Biol Chem       Date:  2005-10-07       Impact factor: 5.157

9.  Disulfide locked variants of factor VIIa with a restricted beta-strand conformation have enhanced enzymatic activity.

Authors:  Henry R Maun; Charles Eigenbrot; Helga Raab; David Arnott; Lilian Phu; Sherron Bullens; Robert A Lazarus
Journal:  Protein Sci       Date:  2005-05       Impact factor: 6.725

10.  Unifying the mechanism of recombinant FVIIa action: dose dependence is regulated differently by tissue factor and phospholipids.

Authors:  Alexey M Shibeko; Samuel A Woodle; Timothy K Lee; Mikhail V Ovanesov
Journal:  Blood       Date:  2012-05-04       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.